Metabolon Releases Potential Noninvasive Biomarkers Identified in Nash Study
RESEARCH TRIANGLE PARK, N.C. (May 13, 2010)— Metabolon, Inc. announces a study published in the Metabolism Journal due for release in the paper on April 26, 2010, by Satish C. Kalhan.
Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon’s patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.
Nonalcoholic steatohepatitis (NASH) is described as inflammation of the liver associated with the accumulation of fat in the liver. NAFLD and NASH occur in individuals who do not consume excessive amounts of alcohol, yet has similarities in what can be seen in liver disease with an excessive intake of alcohol.
Copies of the paper can be accessed through ScienceDirect at: www.metabolismjournal.com.
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.